The Boston Science Harbor Base has been completed and opened, achieving "independent production" in China
qyhyu
发表于 2024-10-16 19:18:25
3120
0
0
On October 15th, the first production and manufacturing base of Boston Scientific China, the Boston Scientific Port Base, was completed and opened, focusing on the production of medical consumables and equipment, enabling the company to achieve "independent production" in China.
It is reported that the Boston Scientific Lingang factory is equipped with leading laboratories in the medical technology industry, advanced production workshops and warehouses, as well as clean rooms that meet both Chinese and international standards. Its overall design integrates new technologies and experiences from Boston Scientific's factories around the world, with the goal of building it into a smart factory with first-class quality and excellent technology worldwide.
Boston Scientific introduces that as an important part of the company's comprehensive localization strategy layout in China, the base will focus on the production of medical consumables and equipment in the future. This will enable the company to achieve "independent production" in China, which will help build a localization strategy layout covering all links of the entire industry chain, including trade, production, research and development, investment, and services, and provide more diversified innovative medical products for Chinese patients.
Zhang Jun, President of Boston Scientific Greater China, stated that the completion of the Lingang factory is an important milestone for Boston Scientific's development in China. The company will rely on the advantages of Lingang to build a more agile and resilient supply chain, in order to respond to local medical and patient needs more timely, quickly, and stably. In the future, the company will continue to increase investment in China, actively cooperate with local suppliers, promote the transformation and upgrading of the local industrial chain with globally unified quality standards, and provide urgently needed innovative medical products for Chinese doctors and patients with high incidence diseases with new quality productivity.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- Interview with Boston Scientific's Gong Wenhao: Proactively embracing the national centralized procurement policy and accelerating the sinking of high-quality medical resources
- Honda accelerates its electrification layout in China, with joint ventures intensively deploying electric vehicles
- Leading independently, foreign investment closely following the trend of extended range hybrid technology sweeping the globe
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- Nvidia expands in China against the trend, attracting talent and adding hundreds of R&D personnel in one year
- Goldman Sachs: Increases Boston Scientific's target price to $103
- Apple is rumored to have preliminary discussions with Tencent and ByteDance to consider embedding their AI models into iPhones sold in China
- Sanofi's BTK inhibitor is declared for market in China